Email ID
Password
Sign me in automatically next time
Published trial adds weight to Takeda's confidence in next-generation antidiabetic

The first full results to be published from a Phase II trial with Takeda's first-in-class oral antidiabetic TAK-875 confirm both efficacy benefits for the GPR40 agonist and a significantly lower...
27 February 2012
Ian Haydock

ian.haydock@informa.com





Please Login to read the full article.
EVENTS
04 April 2016
Stockholm, Sweden
06 April 2016
Hamburg, Germany
JOB OF THE WEEK Promote your job vacancy
© 2016 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36